Clinical value of [ 18 F]F-FDG PET/CT in patients with suspected paraneoplastic dermatoses: Diagnostic performance and impact on clinical management

Jieling Zheng,Yun Yang,Hui Ke,Ru Qian,Zhuo Liu,Weibing Miao

DOI: https://doi.org/10.1016/j.ejrad.2023.111170

IF: 4.531

2023-10-28

European Journal of Radiology

Abstract:Purpose We retrospectively evaluate the diagnostic performance of 2-deoxy-2[ 18 F]fuoro-D-glucose ([ 18 F]F-FDG) PET/CT and its impact on clinical management in patients with suspected paraneoplastic dermatoses (PD). Materials and Methods From an institutional PET/CT database (2014–2022), we retrospectively analyzed patients who were clinically suspected with PD and underwent [ 18 F]F-FDG PET/CT for screening an underlying malignancy. For all scans, positive mucocutaneous lesions and PET-indicated malignancies were assessed, and the degree of FDG avidity among different dermatoses were quantified. The final diagnoses of dermatoses and neoplasms were based on pathologic results, international diagnostic standard and follow-up. We assessed the recommended and applied therapies before and after [ 18 F]F-FDG PET/CT and noted whether the patient management changed on the basis of the [ 18 F]F-FDG PET/CT results. Results We analyzed 60 patients with 10 types of dermatoses in this study. Finally, 19 of the 60 patients who had both of specific dermatosis and contemporaneous neoplasm were diagnosed with PD. [ 18 F]F-FDG PET could identify the underlying neoplasms in 18/19 (94.7%) PD patients, and led to a change of the management in 9/19 (47.4%) PD patients. In addition, the mucocutaneous manifestations of [ 18 F]F-FDG PET/CT associated with several specific dermatoses were characteristic. Conclusions This study highlighted the value of [ 18 F]F-FDG PET/CT as a useful tool for evaluation of patients with suspected PD to unveil the underlying culprit tumor, and profoundly supports the clinical management of PD patients.

radiology, nuclear medicine & medical imaging